RNAseq - Discovery of resistance mechanisms to the BRAF inhibitor vemurafenib in metastatic BRAF mutant melanoma

We propose to biopsy 20 consented BRAF mutant melanoma patients at Addenbrooke's Hospital pre-treatment with vemurafenib and also upon the development of resistant disease, with the aim of using exome sequence and SNP6 data to identify novel sequence variants and copy number alterations that can be used to validate observed resistance mechanisms in our cell line models and also to use these models to inform as to likely candidate small molecule inhibitors to overcome resistance and that could be tested in the clinical trial setting.

Request Access

Studies are experimental investigations of a particular phenomenon. e.g. case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients. Click on one of the Study IDs below to find out more.

Study ID Study Title Study Type
EGAS00001000813 Cancer Genomics
ID File Type Size Located in Quality Control
EGAF00000649629 cram 9.6 GB
EGAF00000649630 cram 9.1 GB
EGAF00000649631 cram 10.6 GB
EGAF00000649632 cram 8.7 GB
EGAF00000649633 cram 9.3 GB
EGAF00000649634 cram 11.3 GB
EGAF00000649635 cram 11.4 GB
EGAF00000656202 cram 11.0 GB
Request Access